Podium Presentation Platelet Rich Plasma and Growth factors

16.1.7 - ADSCs vs PRP in patients with knee Osteoarthritis: Preliminary results of a Randomized Controlled Trial.

Presentation Number
16.1.7
Presentation Topic
Platelet Rich Plasma and Growth factors
Lecture Time
12:09 - 12:18
Session Name
Session Type
Free Papers
Corresponding Author
  • A. Di Martino (Bologna, IT)
Authors
  • A. Di Martino (Bologna, IT)
  • L. Andriolo (Bologna, IT)
  • F. Perdisa (Ozzano Dell'Emilia (BO), IT)
  • A. Sessa (Bologna, IT)
  • A. Boffa (Bologna, IT)
  • S. Altamura (Bologna, IT)
  • G. Filardo (Bologna, IT)
  • S. Zaffagnini (Bologna, IT)
Disclosure
Giuseppe Filardo declares Institutional Support from: Zimmer-Biomet, Cartiheal, Fidia Farmaceutici spa, Finceramica Faenza spa, IGEA Clinical Biophisic, Kensey-Nash, EON medical srl Stefano Zaffagnini declares: Financial support from I+ SRL Royalties fro

Abstract

Purpose

The aim of this study is to evaluate, through a single-blind randomized controlled trial (RCT), the benefit provided by micro-fragmented adipose-derived mesenchymal stem cells (ADSCs) to treat symptomatic knee osteoarthritis (OA) in comparison with a single injection of platelet-rich plasma (PRP), one of the most studied injective treatment currently adopted for this condition.

Methods and Materials

A total of 118 patients were treated with a single intra-articular injection (59 treated with ADSCs and 59 with PRP). Patients were enrolled according to the following inclusion criteria: male or female with age > 18 and < 75; symptomatic knee OA with Kellgren-Lawrence grade of 1-4; failure of at least one conservative treatment for OA knee pain. Up-to-date, 70 patients (35 ADSCs and 35 PRP) were prospectively evaluated up to 6 months after treatment using IKDC subjective, EQ-VAS, and KOOS scores.

Results

At 6 months’ follow-up, both groups presented a significant clinical improvement for all scores. The IKDC subjective score improved from 40.4 to 56.6 in ADSCs group, and from 41.4 to 55.7 in PRP group; the mean EQ-VAS in ADSCs group improved from 64.4 to 71.9, and from 66.0 and 74.3 in PRP group; the KOOS pain improved from 61.0 to 75.9 in the ADSCs group and from 61.5 to 74.1 in the PRP group, and a similar trend was observed also for the other KOOS subscales. No statistically significant difference was found between the two groups at 6 months follow-up.

Conclusion

The preliminary results of this RCT between ADSCs and PRP showed a significant improvement for both groups at 6 months’ follow-up, without any significant difference between the two groups. The analysis of all included patients at the planned 2 years follow-up is needed to confirm these results, in order to provide evidence-based suggestions about the use of ADSCs for the treatment of knee OA.

Collapse